Pulmonology

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.

Pain is a prominent symptom among persons with COPD yet management is not included in clinical guidelines and current research findings are vague, say study authors.

For each of the 6 biologic agents FDA-approved for severe asthma, find the mechanism of action, indication, and biomarkers that predict enhanced response.

Onset of the 2022-2023 RSV season and its end were closer to historical patterns but atypical circulation may continue, say researchers writing in MMWR.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Screening for diabetes by weight will increase diagnoses; weight regain after loss doesn't cancel health benefits; strategy tested to improve RSV detection; and 2 more studies of note.

The burden of RSV-positive acute respiratory infections in older adults during the pre-COVID-19 period was substantial, according to findings from a Mayo Clinic team.

Your daily dose of clinical news you may have missed.

In most patients with viral respiratory infections, the chance of bacterial coinfection is low and antibiotics can be withheld safely, say authors of a new study.

Adding paired serology and sputum to nasal swab/nasopharyngeal swabs RT-PCR increased RSV detection by 50% to 66% on average, respectively.

Dupilumab in patients with uncontrolled COPD reduced annual exacerbations by 30%, a statistically significant and clinically meaningful outcome and a first for a biologic.

Your daily dose of clinical news you may have missed.

Shorter office visit length increased risk for inappropriate antibiotic prescribing, coprescribing of opioids and benzodiazepines, and potentially harmful prescriptions for seniors.

Delivered intranasally, the fully human anti-CD3 mAb Foralumab modulated T-cell inflammation in COVID-19 and may have wider application, say study authors.

The VRBPAC vote that the GSK data support the vaccine's efficacy was unanimous and on safety the vote was 10-2. PDUFA date set for May, 2023.

Your daily dose of clinical news you may have missed.

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

Future studies may consider PARS the new gold standard in predicting pediatric asthma risk, said study authors.

AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.

Pfizer will present pivotal phase 3 data for RSVpreF to the ACIP on February 23; FDA has set a PDUFA date for the vaccine candidate of August 2023.

Your daily dose of clinical news you may have missed.

The CAPTURE tool was able to identify 50% of primary care patients with COPD who could immediately benefit from treatment; experts say, it's a start.

Medical director of the NFID William Schaffner, MD, shares his messages to primary care clinicians as the final months of this year's flu season near.

Your daily dose of clinical news you may have missed.